Clinical evaluation of tumor scanning with 169-Yb-citrate.
169-Yb-citrate was used as the tumor-scanning agent in 360 patients with malignant tumors and in 55 others with benign lesions and the results compared with 67-Ga-citrate studies in other series. In malignant tumors, the overall  positive detection rate for ytterbium was 65.3%; in benign lesions, the false-positive rate was 29.1%. Good results were obtained in the extremities, head and neck, and pelvic area. Of all tumors visualized, squamous cell carcinoma was detected most effectively (77.5%). 169-Yb-citrate has a long shelf life, photon peaks of 178 and 198 kev, clears from the blood more rapidly than 67-Ga-citrate and has an extremely low soft-tissue background uptake. Its main disadvantage is its high radiation dose: 1.74 R/500 muCi whole-body and 5.77 R to the bone.
D000008:Abdominal Neoplasms / Q000175:diagnosis; D000230:Adenocarcinoma / Q000175:diagnosis; D000328:Adult; D001466:Barium Sulfate; D002277:Carcinoma / Q000175:diagnosis; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging; D005189:False Positive Reactions; D006258:Head and Neck Neoplasms / Q000175:diagnosis; D006689:Hodgkin Disease / Q000175:diagnosis; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000175:diagnosis*; D011859:Radiography; D011868:Radioisotopes; D011877:Radionuclide Imaging; D015018:Ytterbium
D011868:Radioisotopes; D001466:Barium Sulfate; D015018:Ytterbium